Pharmacokinetics of Oral Formulations of Gepotidacin (GSK2140944), a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor, in Healthy Adult and Adolescent Participants,Antimicrobial Agents and Chemotherapy

当前位置： X-MOL 学术 › Antimicrob. Agents Chemother. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Pharmacokinetics of Oral Formulations of Gepotidacin (GSK2140944), a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor, in Healthy Adult and Adolescent Participants
Antimicrobial Agents and Chemotherapy ( IF 4.1 ) Pub Date : 2021-10-11 , DOI: 10.1128/aac.01263-21
Aline Barth ₁ , Mohammad Hossain ₁ , Darin B Brimhall ₂ , Caroline R Perry ₁ , Courtney A Tiffany ₁ , Sherry Xu ₁ , Etienne F Dumont ₁

Affiliation

Gepotidacin is a novel, first-in-class triazaacenaphthylene antibiotic that may provide a new treatment option for antibiotic-resistant pathogens. Two pharmacokinetic evaluations of oral gepotidacin are presented; a relative bioavailability study that ...

中文翻译：

Gepotidacin (GSK2140944)（一种三氮杂苊细菌 II 型拓扑异构酶抑制剂）口服制剂在健康成人和青少年参与者中的药代动力学

Gepotidacin 是一种新型、一流的三氮杂苊抗生素，可为耐药病原体提供新的治疗选择。介绍了口服gepotidacin的两种药代动力学评价；一项相对生物利用度研究...

更新日期：2021-10-12

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11